ID   2C4 [Human fibrosarcoma]
AC   CVCL_1D50
DR   cancercelllines; CVCL_1D50
DR   CancerTools; 154235
DR   Wikidata; Q54584423
DR   Ximbio; 154235
RX   PubMed=7901766;
RX   PubMed=9001223;
CC   Population: Caucasian.
CC   Characteristics: Expression of CD2 is under the control of the IFITM1 promoter inducible by interferon gamma.
CC   Sequence variation: Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line).
CC   Genetic integration: Method=Transfection; Gene=HGNC; HGNC:1639; CD2.
CC   Genetic integration: Method=Transfection; Gene=UniProtKB; P00552; Transposon Tn5 neo.
CC   Derived from site: In situ; Bone, pelvis, acetabulum; UBERON=UBERON_0001269.
DI   NCIt; C3043; Fibrosarcoma
DI   ORDO; Orphanet_2030; Fibrosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0317 ! HT-1080
SX   Male
AG   35Y
CA   Cancer cell line
DT   Created: 08-07-15; Last updated: 10-04-25; Version: 19
//
RX   PubMed=7901766; DOI=10.1038/366166a0;
RA   Watling D., Guschin D.Y., Muller M., Silvennoinen O., Witthuhn B.A.,
RA   Quelle F.W., Rogers N.C., Schindler C., Stark G.R., Ihle J.N.,
RA   Kerr I.M.;
RT   "Complementation by the protein tyrosine kinase JAK2 of a mutant cell
RT   line defective in the interferon-gamma signal transduction pathway.";
RL   Nature 366:166-170(1993).
//
RX   PubMed=9001223; DOI=10.1128/mcb.17.2.695; PMCID=PMC231795;
RA   Kohlhuber F., Rogers N.C., Watling D., Feng J., Guschin D.Y.,
RA   Briscoe J., Witthuhn B.A., Kotenko S.V., Pestka S., Stark G.R.,
RA   Ihle J.N., Kerr I.M.;
RT   "A JAK1/JAK2 chimera can sustain alpha and gamma interferon
RT   responses.";
RL   Mol. Cell. Biol. 17:695-706(1997).
//